CandlesenseCandlesense
News/Companies/EPRX

EPRX News

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

EPRX

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

August 12, 2025Earnings
Read more →

Eupraxia Pharmaceuticals Q1 EPS $(0.21) Beats $(0.23) Estimate

EPRX

May 6, 2025
Read more →

Eupraxia Pharma Announces Treatment Outcomes From Ongoing RESOLVE Phase 1b/2a Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis

EPRX

May 5, 2025
Read more →

Eupraxia Pharmaceuticals Q4 Net Profit $(7.5)M Up From $(10.6)M YoY

EPRX

March 20, 2025
Read more →

Eupraxia's EP-104GI Demonstrates Strong Safety And Efficacy In EoE Trial, Paving Way For Higher Dose Exploration

EPRX

February 25, 2025
Read more →

Eupraxia Pharmaceuticals CFO Bruce Cousins To Retire, Alex Rothwell To Assume Role

EPRX

February 18, 2025
Read more →

Eupraxia Pharmaceuticals Unveiled New Pharmacokinetic Data From Its Phase 2A Eosinophilic Esophagitis Program

EPRX

November 20, 2024
Read more →

Rodman & Renshaw Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $9

EPRX

November 14, 2024
Read more →

Eupraxia Pharmaceuticals Announces Additional Positive Clinical Data From Phase 1b/2a RESOLVE Trial Evaluating EP-104GI For Eosinophilic Esophagitis (EoE) - Press Release

EPRX

May 21, 2024
Read more →